Results: During the follow-up, 5 excess deaths per 100 person-years occurred during BZDR use in comparison to nonuse, and mortality rates were 13.4 (95% confidence interval [CI], 12.2-14.5) and 8.5 (95% CI, 7.9-9.1), respectively. Benzodiazepine and related drug use was associated with an increased risk of death (adjusted hazard ratio = 1.4 [95% CI, 1.2-1.6]), and the association was significant from the initiation of use. Benzodiazepine use was associated with an increased risk of death, whereas benzodiazepine-related drug use was not.
| INTRODUCTION
The number of persons with Alzheimer disease (AD) is increasing as the population globally is aging. 1 Alzheimer disease has been associated with a higher frequency of chronic comorbidities 2 as well as an increased risk of adverse health outcomes, including increased need of hospital and institutional care, 3, 4 hip fractures, 5, 6 and mortality, 4 ,7 compared with other older persons.
Therefore, persons with AD constitute a vulnerable population, and the treatment of AD represents a major challenge to healthcare systems.
In addition to cognitive impairment, AD involves also behavioral and psychological symptoms of dementia (BPSD), which are highly frequent in community-dwelling persons with AD, 8 already at the early stages of the disease. 9 Nonpharmacological options are the first-line treatment of BPSDs, and pharmacological options can be used if nonpharmacological treatment approaches have not been effective. 10 Treatment of BPSDs is complex, as the evidence of pharmacological options' efficacy is scarce 11 and the risk of associated adverse outcomes is notable. 10 Benzodiazepines and related drugs (BZDRs) should be used in short-term or infrequent treatment of BPSDs, according to treatment guidelines. 10, 12 Benzodiazepine and related drug use increases considerably at the time of AD diagnosis, 13 and almost one-third of persons with AD use BZDRs after the diagnosis. 14 However, there are only a few studies investigating adverse outcomes associated with BZDR use in persons with AD. Benzodiazepine and related drug use has been associated with an increased risk of hip fracture, stroke, and pneumonia in this population. [15] [16] [17] The risk of these outcomes has been highest in the beginning of BZDR use. These adverse outcomes may predispose BZDR users to an increased risk of death. However, 3 studies investigating the association between BZDR use and mortality in persons with dementia have ended up
with varying results and conclusions, which may result from different methodologies. [18] [19] [20] There are no previous studies focusing specifically on communitydwelling persons with AD. Therefore, our aim in this study was to investigate all-cause 180-day mortality associated with BZDR use initiation in comparison to nonuse in a nationwide cohort of community-dwelling persons with AD.
2 | METHODS
| Cohort
We applied the Medication Use and Alzheimer's Disease (MEDALZ) cohort in this study. 21 The cohort included all community-dwelling persons diagnosed with AD in Finland during 2005 to 2011
(n = 70 718). All data were obtained from nationwide Finnish registers.
Persons with AD were recognized from the Special Reimbursement
Register, which contains information on clinically verified diagnoses of chronic diseases. The validity of AD diagnoses in the Special Reimbursement Register has been demonstrated. 22 The AD diagnoses were based on the National Institute of Neurologic and 
Key points
• New use of benzodiazepines and related drugs was associated with a 41% increase in risk of death in persons with Alzheimer disease.
• The association with an increased risk of death was observed from the initiation of benzodiazepine and related drug use.
• Benzodiazepine use was associated with an increased risk of death, whereas benzodiazepine-related drug use was not.
Benzodiazepine and related drug polypharmacy, ie, use of benzodiazepines and Z-drugs concomitantly, was not investigated separately because of small number of BZDR users with polypharmacy.
| Outcome
The outcome in this study was 180-day all-cause mortality.
| Study setting
We applied a 1-year washout period before the AD diagnosis to exclude prevalent BZDR users. 27 Therefore, all persons who had any BZDR use during the washout period were excluded from the study ( Figure 1 ). Further, persons who were hospitalized/institutionalized for more than 50% of the washout period or who had an ongoing ≥90-day hospital stay at the end of the washout period were excluded. 28 Additionally, persons who were hospitalized/institutionalized throughout the study were excluded.
Each person initiating BZDR use after the AD diagnosis and by 
| Covariates
The covariates obtained from registers included Charlson comorbidity index; socioeconomic position; and histories of chronic cardiovascular diseases, psychiatric disorders, substance abuse, stroke, antidepressant use, antipsychotic use, and opioid use. The collection and definitions of these covariates are described in the Supporting Information.
| Statistical analyses
Continuous covariates were reported with medians and interquartile ranges (IQR), and they were compared with the Mann-Whitney t test.
Categorical covariates were compared with chi-square test.
We calculated the age-adjusted death rate per 100 person-years with 95% confidence intervals (CI) during BZDR use and nonuse. The risk of death was investigated during BZDR use, different durations of BZDR use, and during use of benzodiazepines and Z-drugs separately, in comparison to nonuse. The risk was analyzed with the Cox regression by taking into account the matched design. The associated risks were reported as hazard ratios (HRs) with 95% CIs.
In subanalyses concerning benzodiazepine and Z-drug use separately, persons initiating BZDR use with concomitant use of these drugs, as well as their matched nonusers, were excluded. Further, in these subanalyses, the follow-up was ended at the initiation of use of benzodiazepines and Z-drugs concomitantly.
In multivariable analyses, Charlson comorbidity index, socioeconomic position, 29 histories of hip fracture, psychiatric disorders, substance abuse, 29 and stroke, as well as histories of antidepressant, antipsychotic, and opioid use, were applied as covariates.
In sensitivity analyses, we performed intention-to-treat (ITT)
analyses. In these analyses, the follow-up was not ended at the end of BZDR use or start of long-term hospitalization/institutionalization.
Additionally, we performed subgroup analyses to investigate whether the observed risk of death was dependent on time since AD diagnosis. 30 The interaction between time since AD diagnosis Table 2 ). The subgroup analysis demonstrated that the observed risk of death was not dependent on time since AD diagnosis (P = 0.9470 for the interaction).
| DISCUSSION
Incident BZDR use was associated with an increased 180-day all-cause mortality among community-dwelling persons with AD in this study.
This association was significant from the initiation and remained significant until 4 months of BZDR use. Benzodiazepine use was associated with increased risk of death, while Z-drug use was not.
The sensitivity analyses confirmed our observation of associated risk increase.
Our observation of a 41% increase in the risk of death associated with BZDR use was higher than the observations in the previous studies investigating persons with dementia. [18] [19] [20] In nursing home setting, the risk of 180-day mortality associated with BZDR use was slightly, but not significantly, higher than the risk associated with atypical antipsychotic use. 19 In contrast, we compared the risk initiate BZDR use during the study. 32 These factors might also explain the risk decrease observed by Brännström et al. 20 Older persons, including the vulnerable persons with AD, are susceptible to adverse outcomes of BZDRs because of the age-related changes in pharmacodynamics and pharmacokinetics. 33 The changes increase the central nervous system effects of these drugs in older
persons. Previous studies have demonstrated an increased risk of adverse outcomes associated with BZDR use, including hip fractures and respiratory outcomes, in older persons [34] [35] [36] as well as in persons with AD. 15, 17 Further, BZDR use has been associated with an increased risk of stroke in persons with AD. 16 Alzheimer disease has been associated with increased mortality after hip fractures 6 and pneumonia. 37 Further, stroke is a common cause of death in persons with AD. 38 Therefore, the observed association with an increased risk of death might result from these outcomes. However, a previous study did not demonstrate an association between BZDR use during hip fracture and 1-year mortality after hip fracture. 15 This may relate to the small number of BZDR users investigated in that study. Further research is needed to investigate the mechanism of BZDR-related mortality.
Contrary to our observations in persons with dementia, BZDR use has not been associated with an increased risk of death in community-dwelling older persons. 35, [39] [40] [41] [42] Those studies applied a cross-sectional definition of BZDR exposure based on a baseline 35 an increased risk of death was observed in a subpopulation with no exacerbations during the year before the study.
To our knowledge, the current study is the first one to investigate although also Z-drug use was associated with an increased risk of death. 18 However, in both studies, the difference was small.
Therefore, Z-drug use cannot be considered any safer than benzodiazepine use in persons with dementia regarding risk of death.
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